Every 10-Q that BridgeBio Oncology Therapeutics, Inc (BBOT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBOT filings page.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage oncology company focused on RAS and PI3K malignancies, reported a larger net loss as it ramped development after its 2025 de‑SPAC transaction. For the three months ended June 30, 2026, net loss was $56.5 million, compared with $28.4 million a year earlier; for the first half of 2026, net loss was $98.6 million versus $50.5 million in 2025. Operating expenses doubled year over year, driven by research and development of $49.2 million in the quarter and general and administrative of $11.0 million, including higher public‑company and stock‑based compensation costs.
Despite higher spending, BridgeBio Oncology reported strong liquidity. As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $344.1 million, within total assets of $376.7 million, and the company had 80.1 million common shares outstanding. Management states this cash position is expected to support operations for at least one year from the financial statement issuance date, but the company anticipates continued losses and negative operating cash flows as it advances its pipeline, and it expects to seek additional financing through equity, debt, or partnering arrangements.
BridgeBio Oncology Therapeutics, Inc. reported a net loss of $42.1M for the three months ended March 31, 2026, compared with $22.1M a year earlier, as research and development spending nearly doubled.
R&D expenses rose to $39.8M from $20.6M, while general and administrative costs increased to $6.4M. The company used $35.9M in operating cash during the quarter and ended with $388.9M in cash, cash equivalents, and marketable securities.
Management states this liquidity should fund operations for at least one year from the financial statement issuance date, but the company expects continued losses and anticipates needing additional capital to advance its oncology pipeline and potential commercialization efforts.
BridgeBio Oncology Therapeutics (BBOT) filed its Q3 2025 10‑Q, highlighting a post‑de‑SPAC balance sheet and higher operating spend as programs scale. Cash and cash equivalents were $408.7 million and short‑term marketable securities were $59.5 million, for total liquidity of $468.3 million as of September 30, 2025. The company reported a net loss of $44.8 million for the quarter as operating expenses reached $49.2 million (R&D $35.1 million; G&A $14.1 million), with interest income of $3.4 million and $1.0 million from a transition services agreement.
BBOT completed its de‑SPAC on August 11, 2025, including a $260.9 million PIPE and $120.9 million from the SPAC trust, and ended the quarter with 79,196,710 shares outstanding. For the nine months, net loss was $95.2 million as the company advanced RAS and PI3K oncology programs and established public‑company infrastructure. Management states existing cash, cash equivalents, and marketable securities are expected to support operations for at least one year from issuance.